Research suggests that despite a COVID-19 slump, the anti-Parkinson’s drugs market will recover due to rising numbers of Parkinson’s diagnoses and increasing investment in R&D.
List view / Grid view
Filter the results
A new partnership aims to improve blood-brain-barrier penetration in the nasal drug delivery route for certain Parkinson's therapies.
The implanted biomaterial drug delivery system releases methylprednisolone and reduces inflammation, promoting central nervous system (CNS) repair.
A team has revealed that a patient who received induced pluripotent stem cells to replace lost dopaminergic neurons has reduced symptoms of Parkinson's disease.
According to a new review, multi-arm and multi-stage clinical trials should be used to evaluate potential Parkinson's treatments.
The chitosan drug delivery vehicle could be used for administering polyphenol ellagic acid (EA), a potential antioxidant treatment for Alzheimer’s and Parkinson’s.
Inflazome has announced that the US and EU will grant patents to their NLRP3 inflammasome inhibiting compounds.
Adopting IoT systems as a pharmaceutical company can provide many opportunities but achieving success can be difficult. James Steiner explains how to effectively integrate IoT solutions into pharma.
A document from the DHSC has reportedly advised NHS doctors to ration certain medicines after outlining dozens of drugs that are in shortage, as published in a report.
Scientists have found a way to effectively transport medication into the brain which could lead to improved treatments for neurological and neurodegenerative diseases.
A pioneering clinical study will assess the safety, tolerability and effectiveness of CBD in people with Parkinson's-related psychosis.
PR001 has received Fast Track Designation from the regulatory body for the treatment of Parkinson’s disease.
There are many business challenges to developing a biologics drug, one of which is effective data management. In this article, Unjulie Bhanot focuses on efficient data management policies and systems, and how they could improve biologics product development processes.
A gene therapy called AAV2-GAD has been associated with improved motor function, leading to researchers looking at its use in an upcoming Phase III trial...